DVS-233 SR

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Vasomotor Symptoms

Conditions

Vasomotor Symptoms

Trial Timeline

Dec 1, 2003 → Apr 1, 2004

NCT ID

NCT00421031

About DVS-233 SR

DVS-233 SR is a phase 3 stage product being developed by Pfizer for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00421031. Target conditions include Vasomotor Symptoms.

What happened to similar drugs?

1 of 13 similar drugs in Vasomotor Symptoms were approved

Approved (1) Terminated (0) Active (12)

🔄fezolinetant + placeboAstellas PharmaPhase 3

✅17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved

🔄Bazedoxifene/Conjugated EstrogenPfizerPhase 3

🔄desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3

🔄desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3

🔄Elinzanetant (BAY3427080) + PlaceboBayerPhase 3

🔄Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00092911	Phase 3	Completed	—	May 1, 2005	Depression
NCT00075257	Phase 3	Completed	—	Aug 1, 2005	Major Depressive Disorder
NCT00090649	Phase 3	Completed	—	Mar 1, 2005	Major Depressive Disorder
NCT00063206	Phase 3	Completed	—	May 1, 2004	Major Depressive Disorder
NCT00072774	Phase 3	Completed	—	Nov 1, 2004	Major Depressive Disorder
NCT00073762	Phase 3	Completed	—	Sep 1, 2004	Major Depressive Disorder
NCT00242229	Pre-clinical	Completed	Oct 1, 2004	Oct 1, 2005	Major Depressive Disorder
NCT00256685	Phase 3	Completed	Sep 1, 2004	Jul 1, 2005	Menopause
NCT00421031	Phase 3	Completed	Dec 1, 2003	Apr 1, 2004	Vasomotor Symptoms

Competing Products

20 competing products in Vasomotor Symptoms

See all competitors

Product	Company	Stage	Hype Score
fezolinetant + placebo	Astellas Pharma	Phase 3	40
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiol	Eli Lilly	Phase 2	35
esomeprazole + placebo	AstraZeneca	Pre-clinical	26
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mg	Merck	Phase 2	27
Erenumab + Placebo	Amgen	Phase 1	29
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)	Pfizer	Approved	43
Bazedoxifene/Conjugated Estrogen	Pfizer	Phase 3	40
desvenlafaxine succinate sustained release (DVS SR)	Pfizer	Phase 1	29
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release	Pfizer	Phase 3	40
desvenlafaxine succinate (DVS) SR + Placebo	Pfizer	Phase 3	40
Treatment A + Treatment B + Treatment C	Bayer	Phase 1	26
Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 1	26
Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 3	41
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment B	Bayer	Phase 1	26
Elinzanetant (BAY3427080)	Bayer	Phase 1	26
Moxifloxacin + Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 1	26
Elinzanetant (BAY3427080) + Dabigatran etexilate	Bayer	Phase 1	26
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg	Bayer	Phase 3	37
BAY3427080	Bayer	Phase 1	26
Elinzanetant (BAY3427080) + Rosuvastatin	Bayer	Phase 1	26